Hosted on MSN

Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the company’s twice-a ...

Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...
Hosted on MSN

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending ...
Yahoo

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
Yahoo

Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the ...
Business Wire

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy ...
Dallas Voice

News Is Out hosting Gilead’s Choose U World AIDS Day panel

News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...
Business Wire

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
Seeking Alpha

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...